Arena's Belviq 1st Obesity Drug To Get FDA's Nod Since 1999

Law360, New York (June 27, 2012, 3:26 PM ET) -- The U.S. Food and Drug Administration on Wednesday gave its blessing to Arena Pharmaceuticals Inc.’s weight-loss treatment Belviq, the first such approval in more than a decade and a potential milestone in the nation’s obesity epidemic.

The agency’s action came after years of trouble for diet drugs, which had their reputations tarnished by heart problems associated with fen-phen. The last obesity drug endorsed by the FDA was Roche Holding AG's Xenical, and since it won agency backing in 1999, American waistlines have grown consistently larger....
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required